Mepolizumab reduced exacerbations in COPD with eosinophilia, but missed target
www.pulmccm.org
The injectible monoclonal antibody mepolizumab (Nucala, GSK) is FDA-approved for severe asthma with blood eosinophilia, uncontrolled with standard controller inhaler treatments. Two randomized placebo-controlled trials keep alive for GSK the possibility of an FDA indication to reduce
Mepolizumab reduced exacerbations in COPD with eosinophilia, but missed target
Mepolizumab reduced exacerbations in COPD…
Mepolizumab reduced exacerbations in COPD with eosinophilia, but missed target
The injectible monoclonal antibody mepolizumab (Nucala, GSK) is FDA-approved for severe asthma with blood eosinophilia, uncontrolled with standard controller inhaler treatments. Two randomized placebo-controlled trials keep alive for GSK the possibility of an FDA indication to reduce